93. Primary biliary cholangitis Clinical trials / Disease details
Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03521297 (ClinicalTrials.gov) | January 20, 2020 | 28/4/2018 | Probiotics in PBC Patients of Poor Response to UDCA | Safety and Efficacy of Probiotics in Primary Biliary Cholangitis (PBC) Patients With Poor Ursodeoxycholic Acid (UDCA) Response | Primary Biliary Cholangitis (PBC) | Drug: Probiotic;Dietary Supplement: Placebo | Sun Yat-sen University | NULL | Not yet recruiting | 18 Years | 70 Years | All | 60 | Phase 2 | China |